[
    [
        {
            "time": "",
            "original_text": "业绩高增却‘杀估值’ 绩优医药股或在重构长期机遇",
            "features": {
                "keywords": [
                    "业绩高增",
                    "杀估值",
                    "绩优医药股",
                    "长期机遇",
                    "重构"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "业绩高增却‘杀估值’ 绩优医药股或在重构长期机遇",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]